(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutyric acid | 105181-72-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutyric acid
• 英文别名: (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenyl-butyric acid；(2R,3S)-3-(tert-butyloxycarbonyl)amino-2-hydroxy-4-phenyl-butanoic acid；(2R,3S)-N-(tert-butoxycarbonyl)-3-amino-2-hydroxy-4-phenylbutanoic acid；N-Boc-(2R,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid；N-Boc-(2R,3S)-3-amino-2-hydroxy-4-phenylbutyric acid；Boc-(2R,3S)-3-amino-2-hydroxy-4-phenylbutyric acid；Boc-(2R,3S)-AHPA；(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid
• CAS: 105181-72-4
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: BHTRKISIDQZUQX-NWDGAFQWSA-N

物化性质

• 沸点：
  499.1±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutyric acid 在 盐酸 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 {(S)-1-[(1S,2R)-1-Benzyl-2-hydroxy-2-((8S,11S)-8-isopropyl-7,10-dioxo-2-oxa-6,9-diaza-bicyclo[11.2.2]heptadeca-1(16),13(17),14-trien-11-ylcarbamoyl)-ethylcarbamoyl]-2-methyl-propyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Design and synthesis of broad-Based mono- and bi- cyclic inhibitors of FIV and HIV proteases

  摘要：

  Based on the substrate transition state and our strategy to tackle the problem of drug resistance, a series of HIV/FIV protease (HIV/FIV PR) monocyclic inhibitors incorporating a 15- or 17-membered macrocycle with an equivalent P3 or P3' group and a unique unnatural amino acid, (2R, 3S)-3-amino-2-hydroxy-4-phenylbutyric acid, have been designed and synthesized. In addition, based on the structure of TL3 with small P3/P3' group, we have synthesized two conformationally restricted bicyclic inhibitors containing the macrocycle, which mimic the P1/P1'-P3/P3' tripeptide [Phe-Val-Ala] of TL3. We have found that the contribution of the macrocycle in our monocyclic inhibitors is important to the overall activity, but the ring size does not affect the activity to a significant extent. Several inhibitors that were developed in this work, exhibit low nanomolar inhibitory activity against the wild-type HIV/FIV PR and found to be highly effective against some drug-resistant as well as TL3-resistant mutants of HIV PRs. Compound 15, in particular, is the most effective cyclic inhibitor in hand to inhibit FIV replication in tissue culture at a concentration of 1.0 mug/mL (1.2 muM). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00054-3
• 作为产物：
  描述：

  (2R,3S)-N-(tert-butoxycarbonyl)-3-amino-2-hydroxy-4-phenylbutanoic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutyric acid
  参考文献：
  名称：

  Design and synthesis of broad-Based mono- and bi- cyclic inhibitors of FIV and HIV proteases

  摘要：

  Based on the substrate transition state and our strategy to tackle the problem of drug resistance, a series of HIV/FIV protease (HIV/FIV PR) monocyclic inhibitors incorporating a 15- or 17-membered macrocycle with an equivalent P3 or P3' group and a unique unnatural amino acid, (2R, 3S)-3-amino-2-hydroxy-4-phenylbutyric acid, have been designed and synthesized. In addition, based on the structure of TL3 with small P3/P3' group, we have synthesized two conformationally restricted bicyclic inhibitors containing the macrocycle, which mimic the P1/P1'-P3/P3' tripeptide [Phe-Val-Ala] of TL3. We have found that the contribution of the macrocycle in our monocyclic inhibitors is important to the overall activity, but the ring size does not affect the activity to a significant extent. Several inhibitors that were developed in this work, exhibit low nanomolar inhibitory activity against the wild-type HIV/FIV PR and found to be highly effective against some drug-resistant as well as TL3-resistant mutants of HIV PRs. Compound 15, in particular, is the most effective cyclic inhibitor in hand to inhibit FIV replication in tissue culture at a concentration of 1.0 mug/mL (1.2 muM). (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00054-3

文献信息

• Synthesis of di- and tripeptide analogues containing α-ketoamide as a new core structure for inhibition of HIV-1 protease
  作者：Mahmoud M Sheha、Nadia M Mahfouz、Hoda Y Hassan、Adel F Youssef、Tsutomu Mimoto、Yoshiaki Kiso

  DOI：10.1016/s0223-5234(00)00187-2

  日期：2000.10

  quantitative yields. The alpha-keto tripeptides (18-21) were obtained by oxidation of the hydroxyl group of Apns (PI) in the appropriate tripeptide, iQOA-Val-Apns-(un)substituted Thz(Oxa)-NHBu(t) with DMSO/DCC. Preliminary evaluation of the activity of the synthesized derivatives was determined as percentage of enzyme inhibition at 5 microM and 50 nM levels of the di- and tripeptides respectively. The alpha-ketoamides

  设计和合成了含有α-酮酰胺作为新的核心结构并掺入别苯基去甲他汀（Apns）作为过渡态模拟物的二肽和三肽类似物，希望获得一种新型的HIV-1蛋白酶抑制剂。直接前体Apns-Thz-NHBu（t）是通过Boc-Apns与N-叔丁基丁基Thz-4-羧酰胺盐酸盐偶联制得的。除去Boc基团，然后与各自的α-酮酸残基（P2）偶联，以几乎定量的产率得到所需的二肽（8-12）。通过用适当的三肽iQOA-Val-Apns-（未）取代的Thz（Oxa）-NHBu（t）中的Apns（PI）氧化Apns（PI）的羟基获得α-酮基三肽（18-21） DCC。对合成衍生物活性的初步评估被确定为分别在二肽和三肽的5 microM和50 nM水平下酶抑制的百分比。相对于作为HIV-1蛋白酶抑制剂的母体同等异构体，α-酮酰胺显示出显着增强的效力，并且被证明是酶抑制剂开发的有希望的新核心结构。尝试使用LFE模型的定量方法，将
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• HIV protease inhibitors
  申请人：Wong Chi-Huey

  公开号：US06900238B1

  公开（公告）日：2005-05-31

  Combinatorial libraries of HIV and FIV protease inhibitors are characterized by α-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

  HIV和FIV蛋白酶抑制剂的组合库以α-酮酰胺或羟乙基胺核心结构为特征，一侧为取代吡咯烷、哌啶或氮代糖，另一侧为苯丙氨酸、酪氨酸或取代酪氨酸。这些库是通过一步偶联反应合成的。通过筛选这些库，识别出对HIV和FIV蛋白酶的结合和抑制活性高效的药物候选化合物。对HIV和FIV蛋白酶都显示出临床有用活性的药物候选化合物被确定为潜在对抗由于HIV耐药株的发展而导致的抑制活性丧失。
• Design and synthesis of potent β-secretase (BACE1) inhibitors with <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.gif" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math> carboxylic acid bioisosteres
  作者：Tooru Kimura、Yoshio Hamada、Monika Stochaj、Hayato Ikari、Ayaka Nagamine、Hamdy Abdel-Rahman、Naoto Igawa、Koushi Hidaka、Jeffrey-Tri Nguyen、Kazuki Saito、Yoshio Hayashi、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2006.01.108

  日期：2006.5

  Recently, we reported potent and small-sized beta-secretase (BACE1) inhibitors KMI-420 and KMI-429 in which we replaced the Glu residue at the P4 position of KMI-260 and KMI-360, respectively, with a 1H-tetrazole-5-carbonyl DAP (L-alpha,beta-diaminopropionic acid) residue. At the P1' position, these compounds contain one or two carboxylic acid groups, which are unfavorable for crossing the blood-brain

  最近，我们报道了强效和小型β-分泌酶（BACE1）抑制剂KMI-420和KMI-429，其中我们分别用1H-四唑取代了KMI-260和KMI-360的P4位置的Glu残基-5-羰基DAP（L-α，β-二氨基丙酸）残基。这些化合物在P1'位置含有一个或两个羧酸基团，不利于穿越血脑屏障。在本文中，我们报道了具有P1'羧酸生物异构体的BACE1抑制剂，以开发实用的抗阿尔茨海默氏病药物。其中，含四唑环的化合物KMI-570（IC50 = 4.8 nM）和KMI-684（IC50 = 1.2 nM）表现出显着的BACE1抑制活性。
• Production method of beta-amino-alpha-hydroxycarboxylic acid
  申请人：AJINOMOTO CO. INC

  公开号：US20020151722A1

  公开（公告）日：2002-10-17

  The present invention provides a production method of an optically active &bgr;-amino-&agr;-hydroxycarboxylic acid, which includes the following steps (a)-(c): (a) treating an optically active N-carbamate protected &bgr;-amino epoxide with an acid to give an optically active 5-hydroxymethyl-2-oxazolidinone; (b) oxidizing the resulting compound in the presence of 2,2,6,6-tetramethyl-1-piperidinyloxy and hypochlorite to give an optically active 4-benzyl-2-oxo-5-oxazolidinecarboxylic acid; and (c) treating the 4-benzyl-2-oxo-5-oxazolidinecarboxylic acid with a base, and a production method of an optically active N-carbamate protected &bgr;-amino-&agr;-hydroxycarboxylic acid which includes protection of the amino group with a carbamate type protecting group. The industrial production method of the present invention can produce these compounds efficiently.

  本发明提供了一种光学活性β-氨基-α-羟基羧酸的生产方法，包括以下步骤(a)-(c)：(a) 用酸处理光学活性N-羰基保护的β-氨基环氧化合物，得到光学活性5-羟甲基-2-噁唑烷酮；(b) 在2,2,6,6-四甲基-1-哌啶氧和次氯酸盐存在下氧化所得化合物，得到光学活性4-苄基-2-氧代-5-噁唑烷羧酸；(c) 用碱处理4-苄基-2-氧代-5-噁唑烷羧酸，并且提供了一种光学活性N-羰基保护的β-氨基-α-羟基羧酸的生产方法，其中包括用羰酸酯型保护基保护氨基团。本发明的工业生产方法可以高效地生产这些化合物。